LEXINGTON, Mass.--(BUSINESS WIRE)--July 31, 2006--Critical Therapeutics, Inc. (Nasdaq: CRTX - News) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the twice daily, controlled-release formulation of zileuton (zileuton CR). Zileuton CR is an investigational drug for the prevention and chronic treatment of asthma in adults and children 12 years of age and older. Critical Therapeutics currently markets its asthma drug, ZYFLO® (zileuton tablets), the immediate-release formulation of zileuton, in the United States. ZYFLO is the only 5-lipoxygenase inhibitor approved for marketing by the FDA.
